Jan 17, 2026 | News |
The Centers for Medicare & Medicaid Services has issued formal Government-to-Government receipt confirmation for the Tribal Biotechnology & Health Consortium’s post-market clinical validation evidence submission on Rampart™ DL Matrix (Q4347), submitted under...
Jan 5, 2026 | News |
Following the formal federal identification of Rampart™ DL Matrix (Q4347) as a tribally owned product in the December 15, 2025 CMS Federal Register publication, Clear Health Pass Holdings, in its capacity as Authorized Tribal Agent for the Tribal Biotechnology &...
Dec 15, 2025 | News |
The Centers for Medicare & Medicaid Services today published its CY 2026 Medicare Physician Fee Schedule Policy Update in the Federal Register, formally identifying Rampart™ DL Matrix (HCPCS Q4347) as a tribally owned product in the federal record of covered skin...
Dec 9, 2025 | News |
The Tribal Biotechnology & Health Consortium today transmitted a formal Sovereign Notice to the Centers for Medicare & Medicaid Services, accompanied by an ECHAGA Corporation Board Resolution, requesting that CMS formally recognize the tribal ownership of...
Nov 17, 2025 | News |
The Centers for Medicare & Medicaid Services Coverage and Analysis Group today confirmed receipt of the Tribal Biotechnology & Health Consortium’s post-market clinical validation submission for Rampart™ DL Matrix (Q4347) and confirmed it had forwarded the...
Nov 1, 2025 | News |
The Tribal Biotechnology & Health Consortium today submitted the completed post-market clinical validation of Rampart™ DL Matrix (Q4347) to the Centers for Medicare & Medicaid Services and all seven Medicare Administrative Contractors as a formal sovereign...
